Drug-eluting biostable and erodible stents

J Control Release. 2014 Nov 10:193:188-201. doi: 10.1016/j.jconrel.2014.05.011. Epub 2014 May 17.

Abstract

This paper reviews the latest research and development of drug-eluting stents. The emphasis is on coronary stenting, and both biostable and bioerodible stents are covered in this review. The advantages and shortcomings of the bioactive molecules used in these stents are analyzed, along with the rationale for using bioerodible coatings. The overall emphasis is on the performance of these stents in the clinic. Based on the evaluation of the different stent types, we conclude that fully-erodible stents with a coating of antiproliferative drug will slowly gain market share in the near future, and that the search for a more selective anti-proliferative compound will continue. Dual-drug eluting stents (DDESs) will have their market share but possibly a much smaller one than that for single-drug eluting stents due to the complexities and costs of DDES unless significantly superior performance is demonstrated in the clinic.

Keywords: Biostable drug eluting stent (BDES); Drug release kinetics; Dual-drug eluting stent (DDES); Erodible drug eluting stent (EDES).

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Coated Materials, Biocompatible / adverse effects
  • Coated Materials, Biocompatible / chemistry*
  • Drug Delivery Systems
  • Drug Liberation
  • Drug Stability
  • Drug-Eluting Stents* / standards
  • Humans
  • Myocardial Infarction / prevention & control
  • Pharmaceutical Preparations / administration & dosage*
  • Prosthesis Design / methods*
  • Prosthesis Design / trends

Substances

  • Coated Materials, Biocompatible
  • Pharmaceutical Preparations